Therefore, the aim of the current study was to develop telmisartan derivatives that would have decreased AT1 receptor binding affinity (and consequently reduced AT1 antagonistic activity), thus limiting the antihypertensive effects while maintaining the cytotoxic effects exerted through cancer cell mitochondrial targeting. Here, AGTR1 is linked to cancer.